GSK Plc has agreed to acquire 35Pharma Inc., a biotechnology company developing an early-stage treatment for high blood pressure, in a $950 million deal. The acquisition represents the UK pharmaceutical giant's strategic expansion into the cardiovascular medicine sector, targeting a growing market with significant unmet medical needs.

The transaction comes as pharmaceutical companies increasingly focus on cardiovascular treatments, which represent a substantial portion of global healthcare spending. By acquiring 35Pharma's experimental hypertension medication, GSK gains entry into a competitive field dominated by established players and emerging biotech firms seeking breakthrough therapies.

For 35Pharma, the deal provides substantial funding and the resources of a major pharmaceutical partner to develop its drug candidate. GSK, meanwhile, strengthens its pipeline in cardiovascular disease without bearing full development costs upfront, reflecting a common strategy in the pharmaceutical industry for accessing innovative technologies.